Related references
Note: Only part of the references are listed.Fidaxomicin for the Treatment of Clostridium difficile infections
Craig B. Whitman et al.
ANNALS OF PHARMACOTHERAPY (2012)
Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection
Anna Trzasko et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Mechanism of Action of and Mechanism of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compound LFF571
J. A. Leeds et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Antimicrobial-Resistant Strains of Clostridium difficile from North America
Fred C. Tenover et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Clostridium difficile infection in the community: a zoonotic disease?
M. P. M. Hensgens et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Comparative analysis of an expanded Clostridium difficile reference strain collection reveals genetic diversity and evolution through six lineages
Cornelis W. Knetsch et al.
INFECTION GENETICS AND EVOLUTION (2012)
Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
A Real-World Evaluation of Oral Vancomycin for Severe Clostridium difficile Infection: Implications for Antibiotic Stewardship Programs
Frank Le et al.
PHARMACOTHERAPY (2012)
Epidemiology and control of Clostridium difficile infections in healthcare settings: an update
Frederic Barbut et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2011)
Clostridium difficile infection in Europe: a hospital-based survey
Martijn P. Bauer et al.
LANCET (2011)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study
David T. Rubin et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2011)
In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden
T. Noren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Stuart H. Cohen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Multilocus Sequence Typing of Clostridium difficile
David Griffiths et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Molecular Determinants of Microbial Resistance to Thiopeptide Antibiotics
Sascha Baumann et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Fluoroquinolone Resistance and Clostridium difficile, Germany
Nils Henning Zaiss et al.
EMERGING INFECTIOUS DISEASES (2010)
Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe Refractory Clostridium difficile Infection
Bjorn L. Herpers et al.
CLINICAL INFECTIOUS DISEASES (2009)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
M. P. Bauer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Clostridium difficile in Retail Meat Products, USA, 2007
J. Glenn Songer et al.
EMERGING INFECTIOUS DISEASES (2009)
Vancomycin for the treatment of Clostridium difficile infection:: For whom is this expensive bullet really magic?
Jacques Pepin
CLINICAL INFECTIOUS DISEASES (2008)
Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?
Ed J. Kuijper et al.
CLINICAL INFECTIOUS DISEASES (2008)
Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin
Wafa N. Al-Nassir et al.
CLINICAL INFECTIOUS DISEASES (2008)
Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078
Abraham Goorhuis et al.
CLINICAL INFECTIOUS DISEASES (2008)
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Simon D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005
S. Paltansing et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates
F. Barbut et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Spread and Epidemiology of Clostridium difficile Polymerase Chain Reaction Ribotype 027/Toxinotype III in The Netherlands
A. Goorhuis et al.
CLINICAL INFECTIOUS DISEASES (2007)
Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in the Netherlands
A. Goorhuis et al.
CLINICAL INFECTIOUS DISEASES (2007)
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -: Associated diarrhea, stratified by disease severity
Fred A. Zar et al.
CLINICAL INFECTIOUS DISEASES (2007)
In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004
David W. Hecht et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
Jane Freeman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital
J Freeman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
M Warny et al.
LANCET (2005)
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole
DM Musher et al.
CLINICAL INFECTIOUS DISEASES (2005)
Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract
F Rafii et al.
FEMS MICROBIOLOGY LETTERS (2003)
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin
T Peláez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Reduced susceptibility of Clostridium difficile to metronidazole
JS Brazier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Metronidazole resistance in Clostridium difficile
S Johnson et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
